Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3e9d77ff72f5282325b4e142dfa5b4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 |
filingDate |
1994-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9042cbe1429f99847cb47551d841f466 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f34a242e48f26780f4c3cd193540b76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0b7c79961166b419de32b5953356442 |
publicationDate |
1996-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0721503-A1 |
titleOfInvention |
USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE $g(b)/A4 AMYLOID-INDUCED MORPHOLOGY |
abstract |
The invention provides a composition of matter, comprised of certain oligonucleotides, which inhibit the expression of β/A4 peptide of Alzheimer's disease and Down's Syndrome, and nerve growth factor (NGF) to reverse morphological changes caused in neuronal cells by β/A4 peptide. Further, pharmaceutical compositions, kits and methods for treatment of β/A4 amyloid-induced morphology as well as an assay for screening candidate antisense oligonucleotides effective in treatment of deleterius effects that are visited upon cells by β/A4 amyloid peptide are described. |
priorityDate |
1993-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |